BeiGene, Ltd. (ONC)vsXenon Pharmaceuticals Inc (XENE)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
XENE
Xenon Pharmaceuticals Inc
$55.57
+4.10%
HEALTHCARE · Cap: $5.09B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 71140% more annual revenue ($5.34B vs $7.50M). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
XENE
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for XENE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -51.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : XENE
The strongest argument for XENE centers on Altman Z-Score.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : XENE
The primary concerns for XENE are EPS Growth, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while XENE is a value play — different risk/reward profiles.
XENE carries more volatility with a beta of 0.94 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 22/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Xenon Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company is headquartered in Burnaby, Canada.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?